Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial.

@article{Moohebati2011SimvastatinTR,
  title={Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial.},
  author={Mohsen Moohebati and Shirin Bidmeshgi and Mahmoud Reza Azarpazhooh and Mahdi Hassanzadeh Daloee and Majid Ghayour-Mobarhan and Shima Tavallaie and Maral Amini and Akram Sadat Momenzadeh and Amir Hossein Sahebkar and Roghayeh Paydar and Amir Ali Rahsepar and Seyyed Mohammad Reza Parizadeh and Saeed Akhlaghi and G. A. Ferns},
  journal={Clinical biochemistry},
  year={2011},
  volume={44 2-3},
  pages={192-7}
}
OBJECTIVE This study aimed to evaluate the effects of statin therapy on serum levels of antibodies to several specific heat shock proteins (HSPs) in dyslipidemic patients. DESIGN AND METHODS Participants (n=102) were treated with simvastatin (40mg/day), or placebo in a randomized, double-blind, placebo-controlled, cross-over trial. Anti-HSP60, 65, 70, and hs-CRP levels were measured before and after each treatment period. Seventy-seven subjects completed the study. RESULTS Treatment with… CONTINUE READING
Highly Cited
This paper has 17 citations. REVIEW CITATIONS